XML 34 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Noncontrolling Interests
12 Months Ended
Mar. 31, 2025
Noncontrolling Interest [Abstract]  
Noncontrolling Interests Noncontrolling Interests
Noncontrolling Interests
Noncontrolling interests represent third-party equity interests in the Company’s consolidated entities primarily related to ClarusONE, Vantage, and SCRI Oncology. After June 15, 2021, noncontrolling interests also represented minority shareholder equity interests in McKesson Europe. The Company’s noncontrolling interest in McKesson Europe was included in the divestiture of the E.U. disposal group in October 2022, as discussed in Financial Note 2, “Business Acquisitions and Divestitures.”
Noncontrolling interests in the Company’s Consolidated Balance Sheets were $380 million and $372 million at March 31, 2025 and 2024, respectively. For the years ended March 31, 2025, 2024, and 2023, the Company allocated a total of $186 million, $158 million, and $162 million of net income to noncontrolling interests, respectively.
Changes in noncontrolling interests for the years ended March 31, 2025, 2024, and 2023 were as follows:
(In millions)
Noncontrolling
Interests
Balance, March 31, 2022$480 
Net income attributable to noncontrolling interests162 
Other comprehensive income44 
Payments to noncontrolling interests(150)
Reclassification of recurring compensation to other accrued liabilities(5)
Formation of SCRI Oncology225 
Derecognition of noncontrolling interests in McKesson Europe(382)
Other(7)
Balance, March 31, 2023
367 
Net income attributable to noncontrolling interests158 
Payments to noncontrolling interests(152)
Other(1)
Balance, March 31, 2024
372 
Net income attributable to noncontrolling interests186 
Payments to noncontrolling interests(178)
Balance, March 31, 2025
$380